{"id":1027,"date":"2023-09-21T14:25:12","date_gmt":"2023-09-21T14:25:12","guid":{"rendered":"https:\/\/quantadt.wpengine.com\/us\/?post_type=testimonial&#038;p=1027"},"modified":"2023-09-21T14:25:12","modified_gmt":"2023-09-21T14:25:12","slug":"hooman-hakami-non-executive-director-quanta","status":"publish","type":"testimonial","link":"https:\/\/quantadt.com\/us\/testimonial\/hooman-hakami-non-executive-director-quanta\/","content":{"rendered":"\n<p class=\"wp-block-paragraph\">It is a pleasure to join the Quanta Board. Kidney failure is a growing clinical issue, but the way it has been treated hasn\u2019t fundamentally changed in almost 20 years. As we have seen with the COVID-19 crisis, patients need and want remote, point-of-care solutions. Quanta\u2019s haemodialysis technology and its elegant SC+ system have been designed with this in mind. Because the system is engineered for freedom it is extremely well positioned to drive a transformation in kidney failure management. I look forward to working with the Board and the senior leadership team to achieve the full potential of SC+ and help improve the lives of as many patients as possible.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"content-type":""},"class_list":["post-1027","testimonial","type-testimonial","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/testimonial\/1027","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/testimonial"}],"about":[{"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/types\/testimonial"}],"wp:attachment":[{"href":"https:\/\/quantadt.com\/us\/wp-json\/wp\/v2\/media?parent=1027"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}